|Mr. Steven Lee Yatomi-Clarke||MD, CEO & Director||581.47k||N/A||N/A|
|Ms. Melanie Jaye Leydin B.Bus, C.A., CA||CFO & Company Sec.||N/A||N/A||1973|
|Ms. Leanne West||Director of Clinical Affairs & Operations||N/A||N/A||N/A|
|Dr. Terrence G. Chew||Chief Medical Officer||N/A||N/A||1947|
|Ms. Rebecca Lim||Sr. VP of Scientific Affairs||N/A||N/A||N/A|
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Prescient Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.